## IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant:

Hiroaki SAGAWA ot al.

Conf.:

9947

Appl. No.:

10/509,055

Group:

Unassigned

1422-0644PUS

Filed:

September 24, 2004

Examiner: Unassigned

For:

PROCESS FOR PRODUCING CYTOTOXIC

LYMPHOCYTE

## LARGE ENTITY TRANSMITTAL FORM

#### MS AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

MAY 1 1 2005

#### Sir:

Transmitted herewith is an amendment, sequence listing and disk in the above-identified application.

| The enclose | ed document | is | being | tran  | smitted | via | the | Certificate |
|-------------|-------------|----|-------|-------|---------|-----|-----|-------------|
| of Mailing  | provisions  | of | 37 C  | .F.R. | \$ 1.8. |     |     |             |

The enclosed document is being transmitted via facsimile.

The fee has been calculated as shown below:

|  | CLAIMS<br>REMAINING<br>AFTER<br>AMENDMENT |   | HIGHEST<br>NUMBER<br>PREVIOUSLY<br>PAID FOR |   | PRESENT<br>EXTRA | RATE  | ADDITIONAL<br>FEE |
|--|---|---|---|---|------------------|-------|-------------------|
| TOTAL  | 35  | _ | 35  | = | 0                | \$50  | \$0.00            |
| INDEPENDENT                                      | 7   | _ | 7   | = | 0                | \$200 | \$0.00            |
| FIRST PRESENTATION OF A MULTIPLE DEPENDENT CLAIM |   |   |   |   |                  | \$360 | \$0.00            |
|  |   |   |   |   |                  | TOTAL | \$0.00            |

A. No. 10/509,055

|                | •   | onth(s) extension of time pursuant to136(a). \$0.00 for the extension of  |
|----------------|---|---|
| $\boxtimes$    | No fee is required.                                   |   |
|                | Check(s) in the amount of                             | of \$0.00 is(are) enclosed.   |
|                | Please charge Deposit A<br>\$0.00. This form is subm  | ccount No. 02-2448 in the amount of nitted in triplicate.   |
| overp<br>requi | arrent, and future repli<br>payment to Deposit Accoun | esioner is hereby authorized in this, es, to charge payment or credit any to No. 02-2448 for any additional fees 1.16 or under 37 C.F.R. § 1.17; me fees. |
|                |   | Respectfully submitted,   |
|                |   | BIRCH, STEWART, KOLASCH & BIRCH, LLP  |
| MSW/s<br>1422- | sh<br>-0644PUS1                                       | By ma ~ (6 0040 064)  Marc S. Weiner, #32,181  R.O. Box 747  Falls Church, VA 22040-0747  (703) 205-8000  |

Attachment(s)





## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vigoria 22313-1450 www.uspto.gov

| U.S. APPLICATION NUMBER NO.                 | FIRST NAMED APPLICANT |                               | ATTY, DOCKET NO.             |  |  |
|---|-----------------------|-------------------------------|------------------------------|--|--|
| 10/509,055                                  | Hiroaki Sagawa        | 1                             | 422-0644PUS1                 |  |  |
|   |                       | INTERNATIONAL APPLICATION NO. |                              |  |  |
|   | $\phi$ / $I$          | PCT/JP                        | 03/03575                     |  |  |
| 02292                                       |                       | I.A. FILING DATE              | PRIORITY DATE                |  |  |
| BIRCH STEWART KOLASCH & BIRCH<br>PO BOX 747 | DOCKETED ,            | 03/25/2003                    | 03/25/2002                   |  |  |
| FALLS CHURCH, VA 22040-0747<br>SEL          | g. REG. Sue: 5/17/0   | 371 FORMALITIE                | RMATION NO. 9947<br>S LETTER |  |  |
| ,   |                       | *OC000000015477723            |                              |  |  |

Date Mailed: 03/17/2005

# NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
  - A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e) and PCT Rule 13ter.1(a)(ii).
  - APPLICANT MUST PROVIDE:
    - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
  - For Rules Interpretation, call (703) 308-4216
  - To Purchase Patentin Software, call (703) 306-2600
  - For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice **MUST** be returned with the re

SHELBY J VIGIL

Telephone: (703) 308-9140 EXT 224

## PART 1 - ATTORNEY/APPLICANT COPY

| U.S. APPLICATION NUMBER NO. | INTERNATIONAL APPLICATION NO. | ATTY. DOCKET NO. |
|-----------------------------|-------------------------------|------------------|
|                             |                               |                  |

10/509,055 PCT/JP03/03575

1422-0644PUS1

FORM PCT/DO/EO/922 (371 Formalities Notice)